Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia in HIV-Positive Men
A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men
Sponsor: CIHR Canadian HIV Trials Network
Listed as NCT00428285, this PHASE2 trial focuses on Anus Neoplasms and HIV Infections and remains completed. Sponsored by CIHR Canadian HIV Trials Network, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2019 — Oct 2019 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Feb 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CIHR Canadian HIV Trials Network
- Centre hospitalier de l'Université de Montréal (CHUM)
- McGill University Health Centre/Research Institute of the McGill University Health Centre
For direct contact, visit the study record on ClinicalTrials.gov .